Spyre Therapeutics Inc. SYRE shares are up on Monday following the announcement of positive results from the Phase 2 SKYLINE ...
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the 10 Stocks With Monster Returns. Spyre Therapeutics grew its share prices ...
Investor's Business Daily on MSN
Spyre Therapeutics flies on Takeda-rivaling ulcerative colitis results
Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis ...
What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...
Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...
The great news is that today, there are more effective and diverse treatment options for IBD than ever before, thanks to recent advances in medications and therapies. With so many choices available, ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results